Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Terns Pharmaceuticals Inc
(NQ:
TERN
)
10.45
-0.23 (-2.15%)
Streaming Delayed Price
Updated: 10:06 AM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Terns Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Shares of Terns Pharmaceuticals Soared This Week
March 30, 2023
The company is showing progress toward a NASH therapy.
Via
The Motley Fool
The Latest Analyst Ratings for Terns Pharma
March 29, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 28, 2023
Via
Benzinga
Why Terns Pharmaceuticals Shares Are Trading Higher Today
March 28, 2023
Terns Pharmaceuticals (NASDAQ: TERN) shares are trading higher on Tuesday after the company reported Q4 financial results.
Via
Benzinga
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
March 27, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Appoints Emil Kuriakose, M.D., as Chief Medical Officer of Terns Oncology
March 27, 2023
Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in Oncology
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences
March 02, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2023
February 14, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 7, 2023
February 07, 2023
Via
Benzinga
Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology Conference
February 02, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 01, 2023
Via
Benzinga
Terns Pharmaceuticals to Present at B. Riley Securities’ 3rd Annual Oncology Conference
January 12, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
CommVault Systems, Halozyme Therapeutics And Other Big Stocks Moving Lower On Wednesday
January 11, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Wednesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 12, 2023
Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity...
Via
Benzinga
Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tesla To $250? Here Are 10 Other Price Target Changes For Thursday
December 29, 2022
Morgan Stanley cut Tesla, Inc. (NASDAQ: TSLA) price target from $330 to $250. Morgan Stanley analyst Adam Jonas maintained an Overweight rating on the stock. Tesla shares rose 4.4% to $117.65 in...
Via
Benzinga
$2.4 Million Bet On Duolingo? Check Out These 3 Stocks Insiders Are Buying
December 29, 2022
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
$5.5 Million Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
December 27, 2022
Although US stocks closed higher on Friday, there were a few notable insider trades.
Via
Benzinga
Terns Announces Closing of Public Offering of Shares of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 23, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
BlackBerry, Calavo Growers And Some Other Big Stocks Moving Lower On Wednesday
December 21, 2022
U.S. stocks traded higher, with the Dow Jones gaining over 500 points on Wednesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session
December 21, 2022
Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical...
Via
Benzinga
Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket
December 21, 2022
Gainers ADC Therapeutics SA (NASDAQ: ADCT) shares rose 36.8% to $4.35 in pre-market trading. ADC Therapeutics and Sobi announced European Commission approval of ZYNLONTA for the treatment of relapsed...
Via
Benzinga
Terns Announces Pricing of $75 Million Public Offering
December 20, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
December 20, 2022
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
December 20, 2022
Via
Benzinga
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
December 20, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Terns Announces Proposed Public Offering
December 19, 2022
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
December 19, 2022
Via
Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.